Cantor Fitzgerald analyst Louise Chen came out to defend Valeant Pharmaceuticals (NYSE: VRX) amid competiive concerns raised earlier by Wells ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE